Sangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.23), $0.71 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $12.64 million versus the consensus estimate of $53.09 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.